GlassScriptPhysician profile
Melisa S Steele
NPI 1003923988
$7,294.69
in general payments reported to CMS, 2019-2025
25 companies · $2,113 in 2025
The $2,113 reported for 2025 was more than what 94% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $858 · 2022: $1,734 · 2023: $1,307 · 2024: $1,282 · 2025: $2,113.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,661 · Education: $42.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,660.58 |
| Education | $42.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $2,158.96 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,124.83 | 2021-2025 | Fasenra, Airsupra, Tezspire |
| Amgen INC. | $565.16 | 2022-2025 | Tezspire |
| Glaxosmithkline, LLC. | $497.37 | 2022-2025 | Nucala, Trelegy Ellipta |
| Regeneron Healthcare Solutions, INC. | $468.82 | 2021-2025 | Dupixent |
| Novartis Pharmaceuticals Corporation | $387.52 | 2023-2025 | |
| Kaleo, INC. | $351.64 | 2021-2024 | Auvi-Q |
| Teva Pharmaceuticals USA, INC. | $283.37 | 2021-2022 | |
| Regeneron Pharmaceuticals, INC. | $196.62 | 2023-2025 | Dupixent |
| Grifols USA, LLC | $185.23 | 2023-2025 | Prolastin-C Liquid |
| Pfizer INC. | $137.89 | 2021-2022 | |
| Genentech USA, INC. | $134.97 | 2021-2025 | Xolair |
| Organon LLC | $125.00 | 2025 | Vtama |
| Boehringer Ingelheim Pharmaceuticals, INC. | $115.63 | 2021-2023 | Spiriva Respimat |
| Takeda Pharmaceuticals U.S.A., INC. | $112.85 | 2022-2025 | Cuvitru, Eohilia |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ars Pharmaceuticals Operations, INC. | $96.58 | 2025 | Neffy |
| Optinose US, INC. | $68.30 | 2022-2024 | |
| Sanofi-Aventis U.S. LLC | $65.37 | 2022 | |
| Alk-Abello, INC | $59.98 | 2022-2024 | Odactra, Ragwitek, Grastek |
| Abbvie INC. | $47.50 | 2022 | |
| Bio Products Laboratory USA, INC. | $33.47 | 2022-2023 | Coagadex, Gammaplex |
| Horizon Therapeutics Plc | $23.90 | 2023 | Actimmune |
| Csl Behring | $23.73 | 2022 | |
| Azurity Pharmaceuticals, INC. | $16.15 | 2025 | Alvesco |
| Leo Pharma INC. | $13.85 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melisa Steele listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.